Plasminogen activator inhibitor type-1 mutants regulate angiogenesis of human umbilical and lung vascular endothelial cells
- PMID: 15547731
Plasminogen activator inhibitor type-1 mutants regulate angiogenesis of human umbilical and lung vascular endothelial cells
Abstract
Plasminogen activator inhibitor type-1 (PAI-1) is considered one of the key regulators of tumor invasion, metastasis, as well as cancer-related angiogenesis. The literature suggests that PAI-1 plays a dual role in these processes because it inhibits plasmin-originated proteolysis and binds to vitronectin or integrins. Stimulation or inhibition of angiogenesis largely depends on which of these elements PAI-1 interacts. Wild PAI-1 converts quickly into its latent, inactive form and loses its anti-proteolytic activity, but still binds to vitronectin and integrins. Thus we constructed PAI-1s with extended half-life to prolong their anti-proteolytic activity. We have analyzed the effects of sprout formation inhibition by PAI-1s on two functionally different endothelial cell (EC) systems, human umbilical vein endothelial cells (HUVEC), expressing moderate amounts of urokinase (uPA), and human lung microvascular endothelial cells (HLMVEC), expressing high amounts of this enzyme. We have used wild-type PAI-1 (wPAI-1) (t(1/2) = 1.6 h) and PAI-1 cysteine mutants (CysPAI-1) characterized by their prolonged half-life time (hDbetaT) (t(1/2) = 63.6 h and t(1/2) = 7,000 h). We have observed a significant inhibitory dose-dependent effect exerted by the CysPAI-1s on sprout formation by HUVEC and HLMVEC cells. The inhibition rate was considerably stronger in lung capillary cell cultures and significantly more pronounced for CysPAI-1 mutants with longer anti-uPA activity (betaT). wPAI-1 with a short anti-proteolytic half-life has induced sprout formation in HUVEC, but not in HLMVEC cultures. This difference in behavior was most likely related to the presence of excessive amounts of uPA in HLMVEC cells and the known mechanism of clearing PAI-1/uPA/uPAR complexes from the cell surface. A less efficient system of HUVEC cells might give wPAI-1 the chance to interact with non-proteolytic pathways of angiogenesis stimulation. We conclude that while the anti-proteolytic properties of PAI-1 constructs are preserved, these proteins inhibit angiogenesis and inhibitory activity dominates over any stimulatory effects of PAI-1.
Similar articles
-
Plasminogen activator inhibitor type-1 controls the process of the in vitro sprout formation.J Physiol Pharmacol. 2004 Sep;55 Suppl 3:49-56. J Physiol Pharmacol. 2004. PMID: 15611593
-
Wound-induced migration of MDA-MB-435 and SKOV-3 cancer cells is regulated by plasminogen activator inhibitor-1.Int J Oncol. 2005 Sep;27(3):749-57. Int J Oncol. 2005. PMID: 16077925
-
Pro- and antifibrinolytic properties of human pulmonary microvascular versus artery endothelial cells: impact of endotoxin and tumor necrosis factor-alpha.Crit Care Med. 2004 Jan;32(1):217-26. doi: 10.1097/01.CCM.0000104941.89570.5F. Crit Care Med. 2004. PMID: 14707582
-
uPAR-uPA-PAI-1 interactions and signaling: a vascular biologist's view.Thromb Haemost. 2007 Mar;97(3):336-42. Thromb Haemost. 2007. PMID: 17334498 Review.
-
Protein C and its inhibitor in malignancy.Semin Thromb Hemost. 2007 Oct;33(7):667-72. doi: 10.1055/s-2007-991534. Semin Thromb Hemost. 2007. PMID: 18000793 Review.
Cited by
-
Novel adherent CD11b+ Gr-1+ tumor-infiltrating cells initiate an immunosuppressive tumor microenvironment.Oncotarget. 2018 Jan 29;9(13):11209-11226. doi: 10.18632/oncotarget.24359. eCollection 2018 Feb 16. Oncotarget. 2018. PMID: 29541408 Free PMC article.
-
Defective angiogenesis delays thrombus resolution: a potential pathogenetic mechanism underlying chronic thromboembolic pulmonary hypertension.Arterioscler Thromb Vasc Biol. 2014 Apr;34(4):810-819. doi: 10.1161/ATVBAHA.113.302991. Epub 2014 Feb 13. Arterioscler Thromb Vasc Biol. 2014. PMID: 24526692 Free PMC article.
-
Targeting plasminogen activator inhibitor-1 inhibits angiogenesis and tumor growth in a human cancer xenograft model.Mol Cancer Ther. 2013 Dec;12(12):2697-708. doi: 10.1158/1535-7163.MCT-13-0500. Epub 2013 Sep 26. Mol Cancer Ther. 2013. PMID: 24072883 Free PMC article.
-
Proteolysis is the most fundamental property of malignancy and its inhibition may be used therapeutically (Review).Int J Mol Med. 2019 Jan;43(1):15-25. doi: 10.3892/ijmm.2018.3983. Epub 2018 Nov 7. Int J Mol Med. 2019. PMID: 30431071 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous